Meeting Overview | We are pleased to invite you to our satellite symposium, titled How I Treat Advanced Breast Cancers: A Focus on Targeted Strategies, an Official 2011 European Multidisciplinary Cancer Congress sponsored Satellite Symposium to be held on 26 September 2011 in Stockholm, Sweden. |
Date and Location | Monday, 26 September 2011
18.30-20.00
Stockholmsmässan
Hall T1
Stockholm, Sweden |
Target Audience | This educational activity is specifically designed for medical oncologists, surgical and radiation oncologists, and other healthcare providers interested and/or involved in the treatment of patients with breast cancer. |
Learning Objectives | After successful completion of this educational activity, participants should be able to:
- Describe current standards of care and recent clinical trial data concerning first-line treatment options for patients with HER2-negative metastatic breast cancer, including incorporation of targeted agents when appropriate
- Examine the latest treatment approaches for the management of patients with HER2-positive breast cancer, including utilization of novel therapies and combinatorial strategies
- Evaluate recent clinical trial data regarding treatment of patients with metastatic endocrine-responsive breast cancer
|
Faculty | Chair
Nadia Harbeck, MD, PhD
University of Cologne
Cologne, Germany
Faculty
Hope Rugo, MD
University of California San Francisco
San Francisco, California, United States
Sunil Verma, MD, MSEd, FRCPC
Toronto Sunnybrook Regional Cancer Center
Toronto, Ontario, Canada |
Agenda |
| 18.30 |
Welcome and introduction
Nadia Harbeck, MD, PhD
|
| 18.40 |
How I treat ER-positive progressive metastatic breast cancer
Hope Rugo, MD
|
| 19.00 |
Questions for the experts
|
| 19.05 |
How I treat HER2-negative metastatic breast cancer
Nadia Harbeck, MD, PhD
|
| 19.25 |
Questions for the experts
|
| 19.30 |
How I treat HER2-positive metastatic breast cancer
Sunil Verma, MD, MSEd, FRCPC
|
| 19.50 |
Questions for the experts
|
| 19.55 |
Concluding remarks
|
|
|
|
|
Organizer | This meeting is a prIME Oncology activity.

|
Support | Support for this activity has been provided by unrestricted educational grants from Novartis Oncology and
F. Hoffmann-La Roche Ltd.


|
|